Sprint Bioscience AB represents a set of values and corporate philosophy that drives its operations. With a commitment to innovation and scientific excellence, Sprint Bioscience focuses on discovering and developing novel small molecule drugs for targeted cancer therapies. The company values integrity, collaboration, and transparency in its approach to research and development. By leveraging its expertise in fragment-based drug discovery, Sprint Bioscience aims to deliver transformative treatments that address unmet medical needs. Through its dedication to cutting-edge science and a patient-centric approach, Sprint Bioscience strives to make a positive impact in the field of oncology.

Sprint Bioscience AB is primarily present in Sweden.

Sprint Bioscience AB, a distinguished biotechnology company, has achieved significant milestones throughout its journey. Notably, the company successfully entered into a collaboration with Bayer AG in 2017, demonstrating its recognition as a valuable partner in drug discovery. Furthermore, in 2019, Sprint Bioscience received a prestigious grant from the European Innovation Council's SME Instrument Phase 2 program to support the development of its cancer drug candidate, SB254, highlighting its innovative research and potential for clinical success. With remarkable collaborations and recognition, Sprint Bioscience AB continues to make remarkable strides in the biotechnology sector.

Sprint Bioscience AB is a leading biotechnology company specializing in drug discovery and development. Founded in 2009, the company is headquartered in Stockholm, Sweden. Sprint Bioscience AB focuses on developing innovative treatments for cancer by targeting cancer metabolism. With a dedicated team of scientists and researchers, the company utilizes its cutting-edge drug discovery platform to identify and develop potential drug candidates. By collaborating with renowned academic institutions and industry partners, Sprint Bioscience AB aims to advance its drug pipeline and make a positive impact on patients' lives. With a strong commitment to scientific excellence and a focus on delivering breakthrough therapies, Sprint Bioscience AB continues to drive innovation in the field of oncology.

The main competitors of Sprint Bioscience AB in the market are other pharmaceutical companies that specialize in drug discovery and development. Some notable competitors include AstraZeneca, Pfizer, Novartis, and Merck. These companies also focus on innovative medical solutions and have a strong presence in the biopharmaceutical industry. While Sprint Bioscience AB has its own unique portfolio of drug candidates, it operates in a competitive landscape where these established players constantly strive to bring new and improved therapies to the market.

Sprint Bioscience AB is primarily active in the biotechnology and pharmaceutical industries.

The business model of Sprint Bioscience AB focuses on developing novel cancer therapies through its drug discovery platform. By combining medicinal chemistry and tumor biology expertise, the company aims to identify and develop drug candidates that target specific cancer-related proteins. Sprint Bioscience AB collaborates with pharmaceutical companies to enhance their drug pipelines and potentially bring new treatment options to patients. With a dedication to precision medicine and innovation, Sprint Bioscience AB strives to address unmet medical needs in the field of oncology.

Sprint Bioscience P/E-luku on 4,42.

Sprint Bioscience KUV on 0,95.

AlleAktien Laatuscore Sprint Bioscience on 3/10.

odotettu Sprint Bioscience liikevaihto on 98,98 milj. SEK.

odotettu Sprint Bioscience voitto on 21,16 milj. SEK.

Sprint Bioscience AB is a biopharmaceutical company based in Stockholm, Sweden. Founded in 2009, the company focuses on the discovery and development of drugs for cancer and autoimmune diseases. Sprint Bioscience's business model is based on identifying targeted molecules that play a crucial role in the onset and spread of diseases. These molecules are considered potential drug candidates and are tested in preclinical and clinical trials. The company operates three business divisions that focus on different aspects of drug development: discovery, development, and partnering. Sprint Bioscience's discovery division is responsible for identifying potential drugs. The company has a proprietary technology platform that allows for the systematic and efficient identification and optimization of chemicals. The development division handles the preclinical and clinical testing phases of drug development. The company has its own laboratory facilities for chemical synthesis and analysis of drugs. The partnering division focuses on collaborating with other companies to jointly develop drugs. The company has experience in licensing drug candidates to pharmaceutical companies and also engages in partnership collaborations. Currently, Sprint Bioscience does not offer any products on the market. The company is still in the development phase, and major milestones are expected to be achieved in the coming years. However, Sprint Bioscience has a promising pipeline of drug candidates for various types of cancer and autoimmune diseases. The main drug candidate of Sprint Bioscience is the SB-19 active substance candidate, which has a potential medical application for the treatment of stomach and colorectal cancer. The company recently entered into a collaboration agreement with the American biotech company BioInvent to accelerate the clinical development of SB-19. In 2019, Sprint Bioscience also signed a collaboration agreement with the major Japanese pharmaceutical company Daiichi Sankyo. The collaboration focuses on the discovery of new drug candidates targeting a specific molecule associated with cancer. In summary, Sprint Bioscience's business model is based on the identification and development of new drug candidates for cancer and autoimmune diseases. The company operates three business divisions focusing on different aspects of drug development and has promising drug candidates in its pipeline.

Sprint Bioscience maksaa osinkoa 0 SEK, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Sprint Bioscience:lle tai yhtiö ei maksa osinkoa.

Sprint Bioscience:n ISIN on SE0006343745.

Sprint Bioscience:n WKN on A14NY2.

Sprint Bioscience:n tunnus on SPRINT.ST.

Viimeisen 12 kuukauden aikana Sprint Bioscience maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Sprint Bioscience maksanee ennusteiden mukaan 0 SEK osingon.

Sprint Bioscience:n tämänhetkinen osinkotuotto on .

Sprint Bioscience maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Sprint Bioscience maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 SEK suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Sprint Bioscience kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Sprint Bioscience osingon 9.7.2024, jonka suuruus on 0 SEK, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 9.7.2024.

Viimeisin osinko maksettiin 9.7.2024.

Vuonna 2023 Sprint Bioscience maksoi 0 SEK osinkoina.

Sprint Bioscience:n osingot maksetaan SEKssa.